aeon stock: AEON Biopharma (AEON) Guide

AEON (AEON Biopharma, Inc.)

aeon stock is the ticker symbol for AEON Biopharma, Inc., a clinical‑stage biopharmaceutical company listed on the NYSE American exchange. This guide explains what aeon stock represents in US markets, how the company is organized, where to find trading data and official disclosures, and the main risks and investor considerations associated with a micro‑cap, clinical‑stage biotech. Readers will learn where to verify price and filings, what to expect from liquidity and volatility, and where AEON sits in its clinical pipeline as of the reporting date.

Company overview

AEON Biopharma, Inc. (AEON) is a clinical‑stage biopharmaceutical company focused on developing and commercializing therapeutic products based on proprietary botulinum toxin complex formulations and related biologics. The company's lead candidate historically cited in public disclosures is a botulinum toxin complex referenced as ABP‑450 (prabotulinumtoxinA) or similar formulations intended for aesthetic and therapeutic indications involving neuromuscular modulation.

Founded in the 2010s and headquartered in the United States, AEON operates primarily in research and development, conducting clinical trials, managing regulatory interactions, and pursuing strategic financings and partnerships needed for development progress. As a clinical‑stage enterprise, AEON's operations are R&D‑centric and it typically reports limited or no product revenue while incurring development expenses and operating losses.

Sources for company background include the company's investor relations materials and SEC filings; market aggregators (e.g., Yahoo Finance, Nasdaq) and news coverage also summarize corporate focus and recent disclosures.

Stock ticker and listing information

• Ticker symbol: AEON (commonly referred to in market quotes and platforms as "AEON").
• Exchange: NYSE American (also called NYSE American / AMEX in some market lists). Trading and quotes are denominated in U.S. dollars.
• Typical US trading hours: Regular session is the standard NYSE hours (09:30–16:00 ET); pre‑market and after‑hours trades may be reported separately or with delays depending on data provider.
• Quote delays and data: Some public quote pages (stock aggregators, news sites) may show delayed data or differ by a few seconds; for official time‑stamped trade prints and SEC disclosure timestamps, consult exchange data and SEC filings.

AEON is also visible on retail trading platforms and social trading feeds (e.g., Robinhood and StockTwits report quote and discussion pages), and on market pages such as Yahoo Finance, CNBC, Finviz and Barchart for summaries and historical charts.

Market capitalization and classification

AEON is classified as a micro‑cap company in common market taxonomy. Micro‑cap firms generally have market capitalizations below $300 million, and AEON has historically fallen into the lower end of the micro‑cap spectrum. Micro‑cap classification implies:

• Lower average daily trading volume compared with mid‑cap and large‑cap stocks.
• Wider bid‑ask spreads and higher intra‑session volatility on percentage moves.
• Greater sensitivity to news, financing events and regulatory announcements.

Investors and market observers typically expect AEON's liquidity profile to reflect retail and event‑driven trading patterns rather than the deep, continuous liquidity seen in larger names.

Price history and performance

This section summarizes the price behavior often observed for AEON and describes the typical data points investors watch.

• 52‑week range and major moves: AEON's 52‑week high/low can swing materially in percentage terms (common for micro‑cap biotech names). For precise 52‑week high/low and interval returns (1D, 1M, 3M, 1Y, YTD), consult up‑to‑date market pages such as Yahoo Finance, Nasdaq or Barchart.
• Interval performance: Short‑term performance is frequently event‑driven (clinical readouts, financings, SEC filings); multi‑month and annual performance are influenced by capital raises and regulatory progress.
• Volatility: As a clinical‑stage micro‑cap, AEON typically exhibits higher implied and realized volatility than the broader market; single announcements can produce large percent moves intraday.

Notable corporate actions affecting price

Events that typically have material effects on aeon stock price include:

• Public financings and registered offerings (dilution and cash runway updates).
• Reverse stock splits or share consolidations (may affect per‑share price but not enterprise value).
• Clinical trial updates, interim data releases, or regulatory feedback from authorities such as the U.S. Food and Drug Administration (FDA).
• Business development announcements or licensing deals.
• Securities law enforcement, sponsor changes, or exchange compliance notices.

Each of the above event types has historically produced marked price reactions across the micro‑cap biotech segment and should be tracked via the company's press releases and SEC filings.

Financials and key metrics

As a clinical‑stage company, AEON's financial profile is characterized by limited or no commercial revenue from products and regular R&D and G&A expenses. Key metrics investors commonly monitor include:

• Market capitalization: reflects share count and market price — AEON is categorized as micro‑cap.
• Revenue: usually minimal or non‑material for clinical‑stage biotech unless a licensing revenue stream exists.
• Net loss and cash burn: reported in quarterly and annual 10‑Q/10‑K filings; cash and short‑term investments indicate runway before further financing is required.
• EPS and P/E: Earnings per share is typically negative for loss‑making clinical companies; P/E is not meaningful until sustained positive earnings are reported.
• Debt and convertible instruments: debt balances, convertible notes or structured financings can affect dilution and capital structure.

For accurate numbers (most recent cash balance, quarterly net loss, share count), consult AEON's latest SEC filings and the company investor relations page. Market data aggregators and Reuters/Refinitiv provide quick reference tables for headline figures, but primary reliance should be on company filings for audited or official figures.

Business operations and pipeline

AEON's clinical focus centers on botulinum toxin complex‑based therapeutics, with product candidates typically developed for both aesthetic and therapeutic neuromuscular indications. Key points:

• Lead product candidate: historically referenced as ABP‑450 or prabotulinumtoxinA, a botulinum toxin complex intended for established neuromodulation indications.
• Development stage: clinical‑stage — programs may be in Phase 1/2 or later depending on program and timeline in company disclosures.
• R&D strategy: A mix of clinical trials, investigator‑initiated studies, and potential licensing/partnership discussions to support development and commercialization pathways.
• Regulatory pathway: Interactions with the FDA (and other regulatory agencies as applicable) determine clinical endpoints, trial design and approval milestones.

All clinical and safety details should be verified in the company's clinical trial registry entries, official press releases and SEC filings; this guide does not substitute for those primary sources.

Corporate governance and management

AEON's governance profile and key management are important for assessing execution capability and insider alignment. Typical items to review:

• Executive team: CEO, CFO, Chief Medical Officer and heads of R&D are the primary operational leaders; board composition often includes independent directors with biotech or commercial experience.
• Insider ownership: level of insider and director shareholdings — high insider ownership can align incentives but can also concentrate voting power.
• Governance practices: whether the company uses staggered boards, shareholder rights plans, and other corporate governance structures can be found in proxy statements.

For current names, biographies and insider ownership metrics, consult the company’s most recent proxy statement and investor relations materials, as well as public filing summaries on market data sites.

Regulatory and listing compliance history

AEON’s regulatory timeline and compliance record typically include:

• FDA interactions tied to clinical protocols, IND submissions, or meeting minutes that shape trial execution.
• Exchange notices: NYSE American may issue compliance or extension notices if listing standards are not met (e.g., minimum trading price or market cap thresholds). Any such notices are material and disclosed in public filings or exchange disclosures.
• SEC or regulatory filings: periodic 10‑Q/10‑K filings, current reports (8‑K) for material events.

When assessing regulatory or listing risk, always review the most recent company 8‑K filings and exchange announcements.

Investor relations and communications

AEON maintains investor relations channels to communicate corporate news and regulatory updates. Useful investor resources include:

• Official press releases and corporate presentations issued by the company.
• SEC filings: 10‑Q, 10‑K, 8‑K and proxy statements hosted on the SEC EDGAR system.
• Investor events and webcasts: transcripts or slides for quarterly updates and investor conferences.

Company disclosures are the primary, authoritative sources for corporate progress; market pages and financial news outlets provide summaries and context but should not replace SEC filings for verification.

Trading data and market microstructure

aeon stock trading characteristics commonly observed:

• Average daily volume: as a micro‑cap, average volume can be modest but will spike around news or financing events. Public aggregator snapshots (Yahoo Finance, Barchart, Nasdaq) provide rolling average volume figures.
• Bid‑ask spreads: typically wider than for large‑cap stocks. Wider spreads can increase transaction costs for traders and investors.
• Volatility: heightened; percentage moves on single announcements are common.
• Retail platform presence: AEON appears on several retail trading platforms (example pages include Robinhood and StockTwits) which sometimes increases visibility among retail investors.

As of the reporting date, market activity in aggregated AP most‑active lists shows AEON Biopharma appearing among active NYSE American names (see "Recent developments" below for the AP‑reported figures and timing).

Ownership, short interest, and analyst coverage

• Institutional vs. retail ownership: micro‑cap biotechs frequently have a larger retail investor base relative to institutional ownership, although some small institutions and dedicated biotech funds may hold positions.
• Insider ownership and filings: insider transactions and ownership levels are disclosed in Form 4 filings; these indicate buying/selling activity by executives and directors.
• Short interest: for small names, short interest can be meaningful but may be a smaller share of free float compared with larger companies. Short interest data is available through exchange reporting and market data aggregators.
• Analyst coverage: AEON may have limited sell‑side analyst coverage given its micro‑cap status; public price targets from major brokerages are less common than for large‑cap biotech names.

For current ownership concentrations, short interest and analyst mentions, consult market data pages, the company’s investor relations statements, and regulatory filings.

Risks and considerations for investors

This section outlines typical, factual risk factors specific to AEON and similar clinical‑stage micro‑cap biotechs. These are not investment recommendations — they are factual considerations to verify through the company’s official risk disclosures (e.g., the "Risk Factors" section of its latest 10‑K/10‑Q).

• Clinical and regulatory risk: Clinical trials may fail to meet endpoints, encounter safety issues, or receive unfavorable regulatory feedback. Failure or delay materially affects development timelines and market sentiment.
• Financing and dilution risk: As a company without significant product revenue, AEON may need additional capital through public offerings, private placements or convertible financings — all of which can dilute existing shareholders.
• Liquidity and volatility risk: Low average trading volume can produce wide bid‑ask spreads and large price swings on modest order flow.
• Concentration risk: Significant insider or concentrated shareholdings can affect trading dynamics and corporate control.
• Dependence on partnerships or licensing: If AEON relies on external partners for development or commercialization, counterparty risk and contractual dependencies are considerations.

These risks are commonly enumerated in AEON's public filings and should be reviewed directly in the company's SEC disclosures.

Recent developments (chronological highlights)

• As of Jan 26, 2026, according to an AP markets compilation of most‑active stocks, AEON Biopharma appeared in the NYSE American most‑active list with reported intraday volume figures and prices. The AP list shows AEON Biopharma with reported volume near 1.37 million shares and a last traded price reported in the low‑to‑mid $1.00 range on one AP listing; other AP day‑lists show reported volumes in the 175,000–1.37M range and last trade prices near $1.17–$1.29 depending on the session and list. (Source: AP markets compilation, reported Jan 26, 2026.)

• Company disclosures (press releases and SEC filings) during recent quarters have focused on clinical program updates, financing activities and corporate governance items. For material events (e.g., registered offerings or clinical updates), AEON files 8‑K notices and issues press releases that are the primary sources for timeline verification.

• Market‑level activity: AEON's appearance on NYSE American most‑active lists on multiple AP compilations reflects episodic intraday interest typical of small biotech names when there is news flow, a financing, or other liquidity catalysts. Volume spikes were documented in AP's compiled lists and are consistent with retail and event‑driven trading patterns.

Note: The AP market lists provide snapshot intraday volumes and prices. For authoritative event timing and detail on corporate news (and to reconcile intraday price differentials across lists), consult the company's press releases and SEC filings dated on or near the events.

See also

• Clinical‑stage biotech investing (general primer)
• Biotech regulatory process (FDA submission and approval pathways)
• Micro‑cap stocks: liquidity and market structure
• Botulinum toxin therapeutics and neuromodulation technologies

References

(Primary and commonly used sources for company and market data; consult these sources for verification and the latest numbers.)

• AEON Biopharma — official investor relations and SEC filings (Investor Relations material and 10‑K/10‑Q filings)
• Yahoo Finance — AEON quote and historical price data
• Nasdaq — AEON market activity and listing details
• CNBC — AEON quote and profile summaries
• Finviz — AEON summary tables and news aggregation
• Barchart — AEON quote page and trading statistics
• Robinhood — AEON retail trading page (quote and available metrics)
• StockTwits — AEON symbol feed and community discussion
• Reuters / Refinitiv — company key metrics and reported financials
• AP markets compilation — most active stocks lists (reporting date noted below)

Sources noted above are publicly available market and company data providers; for legal and financial verification, the company’s SEC filings and official investor relations materials are the primary authoritative records.

Reporting date and context

• Reporting date for market activity cited above: As of Jan 26, 2026, according to AP markets coverage of most‑active stocks, AEON Biopharma (AEON) was listed among NYSE American most‑active names with intraday volumes reported in AP's session compilations.

How to verify data and follow AEON going forward

• For price, volume and real‑time quotes: check market data pages such as Yahoo Finance, Nasdaq, Barchart and live broker feeds. Retail platforms and trading terminals also provide streaming quotes.
• For company disclosures: review AEON’s investor relations page and SEC filings (10‑Q, 10‑K, 8‑K and Form 4 for insider transactions).
• For clinical details: review trial registry entries and official press releases describing clinical trial design, endpoints and safety data.
• For community sentiment and intraday chatter: StockTwits and other social feeds show retail discussion; these are supplementary and should not replace primary filings.

Practical notes for market participants (facts, not advice)

• If you are monitoring aeon stock, expect episodic volume spikes and news‑driven volatility. Use official filings for material event confirmation before relying on secondary summaries.
• Micro‑cap biotech companies commonly access capital markets through registered offerings; tracking recent Form S‑3 or registration statements can provide visibility on potential dilution sources.
• For liquidity considerations, examine average daily volume and recent block trades; bid‑ask spreads on smaller tick sizes can significantly affect execution costs.

Additional resources and where Bitget fits in

• For traders interested in exploring cryptocurrency and digital asset services, Bitget provides trading and wallet services tailored to Web3 users. If you use centralized or non‑custodial wallets in your broader portfolio, Bitget Wallet is a dedicated option for Web3 asset management. (This article references Bitget for platform interest and does not imply any endorsement of trading AEON stock on cryptocurrency platforms; AEON is a U.S. equity traded on NYSE American.)

Editorial notes and disclaimers

• This article is informational and neutral in tone. It summarizes public, verifiable facts about AEON Biopharma and aeon stock as of the reporting date and cites typical primary sources.
• This is not investment advice or a recommendation to buy, sell, or hold securities. Readers should consult primary company filings and licensed professionals for financial or legal advice.